The Prediction and Identification of HLA-A*0201 Restricted CTL Epitopes Derived from SOX2 Gene Famil

SESSION TITLE: Lung Cancer II SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: Predict and identify the HLA-A*0201 restricted CTL epitopes with the strongest immunogengenicity of SOX2 antigen. METHODS: Predict and screen the natural epitopes with bioinformatics method. Synthesize peptides in vitro. T2 cells were induced by peptides, and then were used in T2 binding assay. The effective cells were acquired by inducing PBMCs with peptides, and the target cells were acquired by inducing T2 cells with peptides. Then they were used in ELISPOT hIFN-γ and LDH releasing tests. RESULTS: Natural epitopes were obtained: SMYLPGAEV (P1), TLMKKDKYT (P2) and ALGSMGSVV (P3). The binding force between P1 and MHC I increased with the increase of the concentration of peptide, and when the concentration was 50μmol/L and 100μmol/L P1 group was the highest. Effect of killing the target cells can be observed in P1 and P2 group, and the former can secrete more IFN-γ. CONCLUSIONS: SMYLPGAEV is the strongest HLA-A*0201 restricted CTL natural epitope of SOX2 antigen, and may induce a strong immune response in patients with tumor. CLINICAL IMPLICATIONS: This peptide may play an important role in tumor vaccine. DISCLOSURE: The following authors have nothing to disclose: Yu Wang, Jingyan Yuan, Jingyuan Xiao, Wei Li, Na Fan, Wenjing Deng, Boxuan Liu, Ping Fang, Yujie Zhong, Shuanying Yang No Product/Research Disclosure Information